[ad_1]
NIPER scientists claimed to have found that Nimbolide, a chemical compound derived from the leaves and flowers of Neem, can effectively work to cure bad cancer.
They are approaching various agencies such as the departments of Biotechnology, AYUSH, and Science and Technology for funding to continue research and undertake clinical trials, said scientist Chandraiah Godugu.
Scientists at the National Institute for Research and Pharmaceutical Education (NIPER) found that Nimbolide significantly inhibited the growth of bad cancer. he said. Currently, more studies are underway to facilitate clinical trials, says Godugu.
It could also become the least expensive anti-cancer drug by implementing advanced production technology processes, as the Neem was discovered in India. 19659002] In addition to its anticancer property, it may prove to be a promising chemopreventive agent, said Godugu, who is part of the research program. He said that if various parts of a Neem plant were used traditionally to cure multiple disorders, the scientific evidence of their reasoning was lacking.
"We have recently proven the anticancer efficacy of Nimbolide in bad cancer by new molecular pathways, it induces cell death and inhibits the proliferation of cancer cells.
" We have discovered that Nimbolide significantly inhibited the growth of bad cancer and triple negative bad cancer cells … ", he told PTI Neem (Azadirachta Indica) has great value in the Indian medical system and occupies a place important in Ayurveda.It has many properties, such as anti-microbial, anti-cancer, anti-diabetic and anti-inflammatory, says the scientist.
"Its anti-cancer activity has been widely explored, which is largely due to its active ingredient Nimbolide. . It is a novel compound with promising preclinical efficacy against several types of cancer, "said Godugu.
However, clinical translation has been hampered because of the unexplored pharmacokinetics of this new molecule with immense potential for clinical translation
In order to solve the enigma of the oral bioavailability and pharmacokinetics of nimbolide, NIPER has formed a team of experts in the field of pharmacology and badysis Pharmaceutical composition including Shandilya Baira, Amit Khurana, Jaganmohan Somagoni, R Srinivas, Godugu, MVN Kumar Talluri
"Nimbolide can even reduce the serious side effects badociated with chemotherapeutic drugs. As it shows anticancer activity by attacking multiple pathways, the chances of drug resistance are very low.
"It may prove beneficial against the recurrent tumor that poses the challenge of drug resistance, it can even kill dormant and resistant cancer stem cells," said the scientist.
He stated that he expected a clinical translational value formulation in the next four to five years with the entry of the most promising formulation in Phase I clinical trials.
NIPER, Hyderabad, is an "Institute of National Importance" with proclaimed goals to become the Center of Excellence for Advanced Research in Pharmaceutical Sciences.
Follow @htlifeandstyle for more details
[ad_2]
Source link
